CoChat

An omentum-inspired 3D PEG hydrogel for identifying ECM-drivers of drug resistant ovarian cancer

Open access

Published version of a preprint

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Ovarian cancer (OvCa) is a challenging disease to treat due to poor screening techniques and late diagnosis. There is an urgent need for additional therapy options, as patients recur in 70% of cases. The limited availability of clinical treatment options could be a result of poor predictions in early stage drug screens on standard tissue culture polystyrene (TCPS). TCPS does not capture the mechanical and biochemical cues that cells experience in vivo, which can impact how cells will respond to a drug. Therefore, an in vitro model that captures some of the microenvironment features that the cells experience in vivo could provide better insights into drug responses. In this study, we formed 3D multicellular tumor spheroids (MCTS) in microwells and encapsulated them in 3D omentum-inspired hydrogels. SKOV-3 MCTS were resistant to Paclitaxel in our 3D hydrogels compared to a monolayer on TCPS. Toward clinical application, we tested cells from patients [ovarian carcinoma ascites spheroids (OCAS)] who had been treated with Paclitaxel, and drug responses predicted by using the 3D omentum-inspired hydrogels demonstrated the lack of the Paclitaxel response of these samples. Additionally, we observed the presence of collagen production around the encapsulated SKOV-3 MCTS, but not significantly on TCPS. Our results demonstrated that our 3D omentum-inspired hydrogel is an improved in vitro drug testing platform to study the OvCa drug response for patient-derived cells and helped us identify collagen 3 as a potential driver of Paclitaxel resistance in 3D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1063/1.5091713

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Three biomaterial platforms that were used to evaluate the SKOV-3 drug response. (a) Schematic of the MCTS formation method and the experimental setup for drug screening MCTS encapsulated in 3D PEG-MAL hydrogels. (b) Schematic of the components of a 3D PEG-MAL hydrogel with encapsulated SKOV-3 MCTS within a 3D hydrogel. (c) Omentum-inspired integrin-binding peptide cocktail based on healthy omentum proteomic data. (d) Schematic of cells grown on plastic or encapsulated in a 3D hydrogel model. (e) LIVE (green)/DEAD (red) imaging of cells in each platform one day postencapsulation. (f) Ki67 (pink)/DAPI (blue) staining of cells one day postencapsulation to evaluate cell proliferation. Scale bar = 100 μm. Images are representative from N ≥ 2 independent experiments.
FIG. 1. Three biomaterial platforms that were used to evaluate the SKOV-3 drug response. (a) Schematic of the MCTS formation method and the experimental setup for drug screening MCTS encapsulated in 3D PEG-MAL hydrogels. (b) Schematic of the components of a 3D PEG-MAL hydrogel with encapsulated SKOV-3 MCTS within a 3D hydrogel. (c) Omentum-inspired integrin-binding peptide cocktail based on healthy omentum proteomic data. (d) Schematic of cells grown on plastic or encapsulated in a 3D hydrogel model. (e) LIVE (green)/DEAD (red) imaging of cells in each platform one day postencapsulation. (f) Ki67 (pink)/DAPI (blue) staining of cells one day postencapsulation to evaluate cell proliferation. Scale bar = 100 μm. Images are representative from N ≥ 2 independent experiments.CC BY · PubMed Central
FIG. 2. Quantified SKOV-3 drug response reported as EC50 on TCPS or as MCTS encapsulated in RGD or omentum-inspired peptide-binding 3D PEG-MAL hydrogels. (a) Carboplatin. (b) Paclitaxel. (c) Doxorubicin. (d) LY2606368. (e) Mafosfamide. Data are reported as the mean ± SEM. The EC50 values were calculated using the online GR calculator and from N ≥ 2 independent experiments with N = 3 technical replicates on TCPS and N ≥ 2 technical replicates in hydrogels. Statistical significance where p ≤ 0.01 is denoted with **.
FIG. 2. Quantified SKOV-3 drug response reported as EC50 on TCPS or as MCTS encapsulated in RGD or omentum-inspired peptide-binding 3D PEG-MAL hydrogels. (a) Carboplatin. (b) Paclitaxel. (c) Doxorubicin. (d) LY2606368. (e) Mafosfamide. Data are reported as the mean ± SEM. The EC50 values were calculated using the online GR calculator and from N ≥ 2 independent experiments with N = 3 technical replicates on TCPS and N ≥ 2 technical replicates in hydrogels. Statistical significance where p ≤ 0.01 is denoted with **.CC BY · PubMed Central
FIG. 3. OvCa samples derived from patient ascites were encapsulated in 3D omentum-inspired PEG-MAL hydrogels for drug screening. (a) Pathology report of patient samples. (b) LIVE (green)/DEAD (red) imaging of OCAS in 3D omentum PEGMAL hydrogels one day postencapsulation. Scale bars = 100 μm. Images are representative from the sample. (c) Patient sample drug responses displayed as the log2 fold change in EC50 in the omentum hydrogel relative to EC50 on TCPS. Red and blue indicate the higher and lower EC50 values in the 3D omentum hydrogel relative to the EC50 on TCPS, respectively.
FIG. 3. OvCa samples derived from patient ascites were encapsulated in 3D omentum-inspired PEG-MAL hydrogels for drug screening. (a) Pathology report of patient samples. (b) LIVE (green)/DEAD (red) imaging of OCAS in 3D omentum PEGMAL hydrogels one day postencapsulation. Scale bars = 100 μm. Images are representative from the sample. (c) Patient sample drug responses displayed as the log2 fold change in EC50 in the omentum hydrogel relative to EC50 on TCPS. Red and blue indicate the higher and lower EC50 values in the 3D omentum hydrogel relative to the EC50 on TCPS, respectively.CC BY · PubMed Central
FIG. 4. Immunofluorescence staining of SKOV-3 cells demonstrated that they produce their own ECM proteins over the time frame of a drug screening assay. (a) Fibronectin (green)/DAPI (blue). Fibronectin can be seen on plastic as well as between cells in the MCTS. (b) Collagen 1 (green)/DAPI (blue). Collagen 1 production was not observed on plastic but was visible around the spheroids. (c) Collagen3A1 (pink)/DAPI (blue). Some collagen 3A1 may be present on plastic but is clearly visible surrounding the spheroids in both hydrogels. Scale bars = 100 μm. Images are representative from N ≥ 2 independent experiments.
FIG. 4. Immunofluorescence staining of SKOV-3 cells demonstrated that they produce their own ECM proteins over the time frame of a drug screening assay. (a) Fibronectin (green)/DAPI (blue). Fibronectin can be seen on plastic as well as between cells in the MCTS. (b) Collagen 1 (green)/DAPI (blue). Collagen 1 production was not observed on plastic but was visible around the spheroids. (c) Collagen3A1 (pink)/DAPI (blue). Some collagen 3A1 may be present on plastic but is clearly visible surrounding the spheroids in both hydrogels. Scale bars = 100 μm. Images are representative from N ≥ 2 independent experiments.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. L. Jansen, T. McCarthy, M. Lee, and S. Peyton, preprint bioRxiv (2018).
  2. E. A. Brooks, S. Galarza, M. F. Gencoglu, R. C. Cornelison, J. M. Munson, and S. Peyton, preprint bioRxiv (2018).
  3. A. O. Mueck, H. Seeger, D. Wallwiener, and J. Huober, Eur. J. Gynaecol. Oncol. 25(6), 699– 701 (2004). 15597845

Cited by

See all 52

Metadata

Authors
Brooks, E. A., Gencoglu, M. F., Corbett, D. C., Stevens, K. R., & Peyton, S. R.
Affiliations
  • University of Massachusetts Amherst (US)
  • University of Washington (US)
Corresponding author
Peyton, Shelly R.
Venue
APL Bioengineering
Published
2019-06-01
Volume
3
Issue
2
Pages
026106-026106
ISSN
2473-2877 (ISSN-L)
OpenAlex
W2954618703
Cited by
51
References
54
Citations by year
2026: 1 · 2025: 9 · 2024: 3 · 2023: 4 · 2022: 12 · 2021: 8 · 2020: 11 · 2019: 3
FWCI
3.00
Type
journal article
Language
en
Open access
Licence
Locations
  • APL Bioengineering (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Scholarly Commons (University of the Pacific) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • ScholarWorks@UMassAmherst (University of Massachusetts Amherst) (submittedVersion, cc-by)
Funders
  • Barry and Afsaneh Siadat (Career Development Award)
  • National Science Foundation (1454806)
  • National Institutes of Health (1DP2CA186573-01, T32 GM008515)
  • Pew Charitable Trusts (Research Scholar Award)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
Keywords
ovarian cancer, drug resistance, paclitaxel resistance, poly(ethylene glycol) hydrogels, microwells, extracellular matrix, type III collagen, SKOV3 cells, in vitro drug testing, collagen synthesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.